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The Krüppel-like factor 9 cistrome in mouse
hippocampal neurons reveals predominant
transcriptional repression via proximal
promoter binding
Joseph R. Knoedler1,3, Arasakumar Subramani2 and Robert J. Denver1,2*
Abstract
Background: Krüppel-like factor 9 (Klf9) is a zinc finger transcription factor that functions in neural cell
differentiation, but little is known about its genomic targets or mechanism of action in neurons.
Results: We used the mouse hippocampus-derived neuronal cell line HT22 to identify genes regulated by Klf9,
and we validated our findings in mouse hippocampus. We engineered HT22 cells to express a Klf9 transgene under
control of the tetracycline repressor, and used RNA sequencing to identify genes modulated by Klf9. We found
217 genes repressed and 21 induced by Klf9. We also engineered HT22 cells to co-express biotin ligase and a Klf9
fusion protein containing an N-terminal biotin ligase recognition peptide. Using chromatin-streptavidin precipitation
(ChSP) sequencing we identified 3,514 genomic regions where Klf9 associated. Seventy-five percent of these
were within 1 kb of transcription start sites, and Klf9 associated in chromatin with 60% of the repressed genes.
We analyzed the promoters of several repressed genes containing Klf9 ChSP peaks using transient transfection
reporter assays and found that Klf9 repressed promoter activity, which was abolished after mutation of Sp/Klf-like
motifs. Knockdown or knockout of Klf9 in HT22 cells caused dysregulation of Klf9 target genes. Chromatin
immunoprecipitation assays showed that Klf9 associated in chromatin from mouse hippocampus with genes
identified by ChSP sequencing on HT22 cells, and expression of Klf9 target genes was dysregulated in the
hippocampus of neonatal Klf9-null mice. Gene ontology analysis revealed that Klf9 genomic targets include
genes involved in cystokeletal remodeling, Wnt signaling and inflammation.
Conclusions: We have identified genomic targets of Klf9 in hippocampal neurons and created a foundation
for future studies on how it functions in chromatin, and regulates neuronal morphology and survival across
the lifespan.
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Background
Krüppel-like factors (Klfs) comprise a family of zinc-finger
transcription factors (TFs) that function in metabolism,
development and oncogenesis [1]. They have a highly
conserved DNA binding domain comprised of three zinc
fingers that binds GC/GT rich regions in the genome.
Members of this family are distinguished by their highly
divergent N-terminal domains which recruit different
chromatin modifying factors that in part govern whether
the Klf functions as a transcriptional activator or repressor
[1]. Krüppel-like factor 9 (Klf9; formerly basic transcrip-
tion element binding protein 1 – BTEB1) was identified in
a screen of a rat liver cDNA library for proteins that bind
the basic transcription element (BTE), a GC-rich motif in
the promoter of the rat Cyp1a1 (Cytochrome P450) gene
[2]. The zinc fingers of Klf9 have high sequence identity
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with those of Specificity protein 1 (Sp1), which binds to
similar motifs and typically activates transcription [2].
Transient transfection assays showed that Klf9 repressed
transcription from a reporter construct containing the
BTE sequence. However, Klf9 activated transcription from
a reporter containing six tandem repeats of the BTE,
suggesting that its activity may be governed by the num-
ber of binding sites at a locus [2]. The N-terminal region
of Klf9 contains two separable transactivation domains
required for full activation of the six-repeat BTE promoter,
and an α-helical motif that interacts with the repressor
protein Swi-independent 3a (Sin3a) [3, 4].
In mouse central nervous system (CNS) Klf9 expression
is low at birth, rises postnatally, and peaks at approxi-
mately postnatal day (PND) 30 with highest expression in
the hippocampus and cerebellum [5, 6]. This postnatal in-
crease in Klf9 expression depends on thyroid hormone
(TH), which acts via its nuclear receptors to directly regu-
late transcription of the Klf9 gene [7–10]. In immature
and developing neurons, Klf9 mediates actions of TH on
neurite extension [8, 11, 12]. However, in mature cortical
neurons Klf9 inhibits neurite outgrowth [13], while in the
cerebellum it mediates TH-dependent inhibition of
axonal regeneration [14]. Thus, in neuronal cells Klf9
first promotes, then maintains the differentiated state.
It is also required for survival of adult-born dentate
granule neurons and Purkinje neurons of the cerebel-
lum [15, 16], and it promotes oligodendrocyte differen-
tiation and the expression of myelinating genes [17].
Consistent with these findings, Klf9-null mice show
neurological defects, including deficits in fear conditioning
and late-stage neurogenesis [6, 16]. In addition to its
developmental role, Klf9 is also an immediate-early gene
that is upregulated in neurons by many extracellular
stimuli, including TH [8], glucocorticoids [18], and elec-
trical activity [16].
Despite evidence for a diversity of developmental and
physiological roles for Klf9, very little is known about
Klf9 genomic targets in any cell type, and nothing is
known about the genes that Klf9 regulates in neurons.
In the present study, we identified direct genomic targets
of Klf9 in the mouse hippocampus-derived neuronal cell
line HT22, which is a model for mature hippocampal neu-
rons. This cell line expresses neuronal markers such as
enolase and neurofilament proteins, but does not express
the glial marker glial fibrillary acidic protein [19, 20]. We
engineered several HT22 cell lines to allow for control of
Klf9 expression to study Klf9-dependent transcriptional
responses by RNA sequencing (RNA-seq); to identify
genomic regions where Klf9 associates in chromatin by
chromatin-streptavidin precipitation followed by deep se-
quencing (ChSP-seq); and to investigate the consequences
of Klf9 deletion for gene transcription and cell prolifera-
tion (using CRISPR/Cas9 genome editing). We validated
our findings in HT22 cells by analyzing Klf9 association in
chromatin in mouse hippocampus by chromatin immuno-
precipitation (ChIP) assay, and mRNA levels for putative
Klf9 target genes in wild type and Klf9-null mouse
hippocampus.
Results
Validation of engineered HT22 cell lines for the
identification of Klf9 genomic targets
We stably transfected HT22 cells with pCDNA4:TO-
Klf9 and pCDNA6:TR vectors (see Methods), then
isolated and screened seven clonal lines for baseline
and doxycycline (dox)-inducible Klf9 mRNA. One
clonal cell line (2–1) was selected for further analysis.
The mean baseline Klf9 mRNA level of this cell line
(hereafter referred to as HT22 [TR/TO-Klf9]) was
slightly higher than that of the parent line, but this was
not statistically significant (Fig. 1a). After treatment with
dox for 8 h Klf9 mRNA increased by ~10-fold (Fig. 1a;
F (3,8) = 480.974, p < .001; n = 3/treatment; ANOVA),
which is within the physiological range seen following
hormone treatment in HT22 cells, in neonatal mouse
brain following hormone treatment [7], and in mouse
brain during development [5].
We were unable to detect the endogenous (native) or re-
combinant (dox-induced) Klf9 protein by Western blot-
ting on nuclear extracts of HT22 cells (data not shown),
or with extracts from different cells/tissues of mouse or
Xenopus using different antiserums (J.R. Knoedler, P.
Bagamasbad and R.J. Denver, unpublished data). We
therefore developed a bioassay that served as a proxy for
the level of functional Klf9 protein in the cell. This assay
comprised transient transfection of HT22 [TR/TO-Klf9]
cells with a luciferase reporter vector containing three tan-
dem repeats of the BTE sequence (pGL4.23-3xBTE),
which supports Klf9-dependent transactivation or
transrepression depending on the cell type [2, 10]; a
promoter-less luciferase vector (pGL4.23) served as
control. Treatment with dox for 8 h reduced luciferase
activity by 20% in cells transfected with pGL4.23-
3xBTE, but did not alter luciferase activity in empty
pGL4.23 vector-transfected cells (Fig. 1b; t (5) = 3.752, p
< .05; Student’s two-sample t-test). To independently
confirm that Klf9 represses activity from this promoter
we co-transfected the parent HT22 cell line with
pGL4.23-3×BTE and the pCS2-Klf9 expression vector.
This produced a statistically significant reduction (39%)
in luciferase activity compared with cells transfected
with empty pCS2 vector (Additional file 1: Figure S1; t
(6) = 3.292p < .05; Student’s two-sample t-test). Taken
together, our results show that Klf9 mRNA can be in-
duced within the physiological range by dox treatment
of HT22 [TR/TO-Klf9] cells, and that this leads to the
production of functional Klf9 protein.
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Identification of Klf9-regulated genes in HT22 [TR/TO-
Klf9] cells by RNA sequencing
We conducted RNA sequencing (RNA-seq) on parent
HT22 cells and the HT22 [TR/TO-Klf9] cell line treated
with vehicle or dox for 8 h (n = 3/treatment for the par-
ent line, 3 for HT22 [TR/TO-Klf9] vehicle treated and 2
for HT22 [TR/TO-Klf9] dox treated; a third replicate
had to be discarded due to a technical error). We aligned
sequencing reads to the mm8 build of the mouse gen-
ome using Bowtie [21], and differences in transcript
abundance were quantified using DESeq [21, 22]. The
parent HT22 cell line treated with dox showed no gene
expression differences compared to parent cells treated


















Fig. 1 Identification of Klf9-regulated genes in HT22 cells by RNA-sequencing. a Treatment of HT22 [TR/TO-Klf9] cells with doxycycline (dox; 1 μg/
ml) for 8 h increased Klf9 mRNA ~10 fold compared to vehicle treated cells, but had no effect in parent HT22 cells. The baseline Klf9 mRNA level
did not differ between parent and [TR/TO-Klf9] line. Means with the same letter are not significantly different (p < .05; ANOVA followed by Tukey’s
post-hoc test). b Dox-induced expression of Klf9 reduces luciferase activity from the pGL4.23-3xBTE plasmid, but not from pGL4.23-empty. The
asterisk indicates a statistically significant difference by Student’s two-sample t-test (p < .05). c Validation by RTqPCR of four genes found to be
repressed by Klf9 by RNA-seq. Treatment with dox for 8 h reduced mRNA levels for the four genes in HT22 [TR/TO-Klf9] but not in parent HT22
cells. The asterisks indicate statistically significant differences from parent cells treated with vehicle or dox, and from HT22 [TR/TO-Klf9] cells treated
with vehicle (p < .05; ANOVA followed by Tukey’s post-hoc test). d Time-course showing induction of Klf9 mRNA following treatment of HT22
[TR/TO-Klf9] cells with dox. e Validation of repression (9 genes) or induction (3 genes) of Klf9 target genes after treatment of HT22 [TR/TO-Klf9]
cells with dox for different times. The asterisks indicate statistically significant differences from the zero time point (p < .05; ANOVA followed
by Tukey’s post-hoc test)
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supporting that dox treatment does not have a signifi-
cant impact on the HT22 transcriptome. We next
compared the vehicle and dox-treated HT22 [TR/TO-
Klf9] cells and found 238 differentially expressed
genes, 217 downregulated and 21 upregulated (FDR-
adjusted p < .005). The changes in mRNA level after
8 h of dox treatment ranged from − 1.2 to 1.52 (log2
fold change). The top 10 most strongly induced and
repressed genes are listed in Table 1, and a list of all
differentially regulated genes is given in Additional
file 2: Table S1. We validated repression by Klf9 of 4
genes by RTqPCR on RNA isolated from parent and
HT22 [TO/TR-Klf9] cells treated with vehicle or dox for
8 h (Fig. 1c; Klf13: F (3,19) = 7.708, p < .005; Limk1: F (3,17)
= 6.417, p < .005; Mapk11: F (3,19) = 22.107, p < .001;
Pou6f1: F (3,19) = 4.286, p < .05; n = 4–6/treatment;
ANOVA).
To further validate our RNA-seq data set, and to in-
vestigate the kinetics of Klf9-dependent gene repres-
sion, we conducted RTqPCR on HT22 [TO/TR-Klf9]
cells treated with dox for different times. We observed
a statistically significant increase in Klf9 mRNA by
2 h, which peaked at 4 h and remained elevated
through 24 h of dox treatment (Fig. 1d; F (5,16) = 14.97,
p < .001; n = 4/time point; ANOVA). We then con-
ducted RTqPCR on 10 Klf9-repressed and 6 Klf9-
induced genes with log2 fold changes ranging from − 0.44
to − 1.12 for repressed, or 0.38 to 0.56 for induced
genes. We validated 9 repressed genes (Fig. 1e; Klf13: F
(5,16) = 6.642, p < .001; Limk1: F (5,15) = 4.048, p < .05;
Mapk11: F (5,16) = 4.787, p < .01; Pou6f1: F (5,15) = 4.527,
p < .05; Klf16: F (5,14) = 6.914, p < 0.05; Apc2: F (5,16) =
5.548, p < .005; Nlgn2: F (5,16) = 3.185, p < .05; Smurf1: F
(5,16) = 4.689, p < .01; Nyap1: F (5,16) = 3.474, p < .05; n =
4/time point; ANOVA). Messenger RNA for Hhipl was
unaffected (data not shown). However, of the 6 Klf9-
induced genes tested, we could validate only 3 (Frk,
Tctn2 and Cdkn3; Mitd1, Rilpl2 and Ostm1 mRNAs
were unaffected; data not shown). The mRNAs of the 3
induced genes that we validated were increased follow-
ing 8–12 h of dox treatment, but returned to baseline
by 24 h (Fig. 1e; Frk: F (5,12 = 4.721, p < .05; Tctn2: F
(5,16) = 3.055, p < .05; Cdkn3: F (5,14) = 3.736, p < .05; n =
4/time point; ANOVA).
Identification of sites across the HT22 genome where Klf9
associates in chromatin
We engineered HT22 cells to express the E. coli biotin
ligase BirA (HT22 [BirA]) or BirA plus a Klf9 fusion
protein with an N-terminal FLAG tag and biotin ligase
recognition peptide (HT22 [BirA/FLBIO-Klf9]) [23].
This allowed for high-affinity purification of Klf9 in
chromatin by streptavidin precipitation (ChSP). We
used Western blotting to detect the biotinylated fusion
protein with streptavidin-HRP in HT22 nuclear extract
(Fig. 2a). Previous work showed that Klf9 associates in
chromatin with the Klf13 5′ upstream region in NIH
3 T3 cells (M. Nikiforov, unpublished results). We
therefore investigated if Klf9 associated in chromatin
with this genomic region in HT22 cells as proof-of-
principle for the ChSP technique. First, we conducted
ChIP assay for Klf9 on chromatin from the parent
HT22 cell line. This resulted in ~5 fold enrichment
above background (determined by ChIP with normal
goat IgG) at the Klf13 promoter but not at a Klf13
intronic region which lacks Sp/Klf motifs (Additional
file 3: Figure S2; intronic region, t (6) = .850, p = .428;
promoter region, t (6) = 3.607, p < .05; n = 4/treatment;
Student’s two-sample t-test). Next, we conducted ChSP
on chromatin from HT22 [BirA] and HT22 [BirA/
FLBIO-Klf9] cells. This resulted in ~25 fold enrichment
Table 1 The top ten most up- or down-regulated genes by
eight hr of forced Klf9 expression in HT22 [TR/TO-Klf9] cells
(FDR-adjusted p value cutoff of .005)
Gene Symbol Gene name Log2 fold
change
Klf13 Krüppel-like factor 13 −1.21
Rptoros Regulatory associated protein of
MTOR, complex 1, opposite strand
−1.12
Gpr161 G Protein-coupled receptor 161 −1.11
Apc2 Adenomatosis polyposis coli 2 −1.04
Zfp704 Zinc finger protein 704 −1.02
Arhgap39 Rho GTPase Activating Protein 39 −0.96
Armc7 Armadillo Repeat Containing 7 −0.95
Mex3a Mex-3 RNA Binding Family
Member A
−0.92




Frk Fyn-Related Src Family Tyrosine
Kinase
0.43
1810043G02Rik RIKEN cDNA 1810043G02 0.46
4930430 F08Rik RIKEN cDNA 4930430 F08 0.47
2610301B20Rik RIKEN cDNA 2610301B20 0.48
Tctn2 Tectonic Family Member 2 0.49
Arxes2 adipocyte-related X-chromosome expressed
sequence 2
0.51
Mitd1 Microtubule Interacting and Transport
Domain Containing 1
0.51
Rilpl2 Rab Interacting Lysosomal Protein-Like 2 0.51
Zfp930 Zinc-finger protein 930 0.52
Cdkn3 Cyclin-Dependent Kinase Inhibitor 3 0.56
The mRNA levels (counts) were evaluated by DESeq. Genes are ordered by
log2 fold change (lowest to highest). A complete list of differentially regulated
genes is given in The mRNA levels (counts) were evaluated by DESeq. Genes
are ordered by log2 fold change (lowest to highest). A complete list of
differentially regulated genes is given in Additional file 2: Table S1
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above background (ChSP on chromatin from HT22
[BirA]) at the Klf13 promoter but not at the same Klf13
intronic region (Fig. 2b; t (6) = −8.315, p < .0005; n = 4/
cell line; Student’s two-sample t-test). These findings
support that both native Klf9 and the FLBIO-Klf9 fu-
sion protein associate in chromatin at the Klf13 locus,
and that the ChSP technique results in a greater signal/
noise ratio than ChIP assay.
Fig. 2 Identification of genome-wide association of Klf9 in HT22 cell chromatin using chromatin-streptavidin precipitation sequencing. a HT22
[BirA/FLBIO-Klf9] cells express biotinylated Klf9. Whole cell extracts from the HT22 parent cell line (lane 1), HT22 [BirA] cells (lane 2) or HT22 [BirA/
FLBIO-Klf9] (lane 3) were fractionated on 10% SDS-PAGE and analyzed by Western blotting using streptavidin-HRP. b Chromatin-streptavidin
precipitation gives ~25-fold enrichment at the Klf13 promoter in HT22 [BirA/FLBIO-Klf9] cells compared with HT22 [BirA] cells. Precipitated DNA
was analyzed by qPCR at the Klf13 promoter and intron (negative control region). The asterisk indicates a statistically significant difference by
Student’s two-sample t-test (p < .0005). c Genome Browser (University of California, Santa Cruz) views showing the location of Klf9 peaks at eight
Klf9-repressed genes. Top track = reads from cells expressing BirA alone; bottom track = cells expressing BirA + FLBIO-Klf9. The 5′ flanking region of
each locus is shown; bars below the peaks represent exons, lines represent introns. d Validation of ChSP-seq peaks (shown in C) by targeted ChSP
with quantitative PCR. Chromatin isolated from HT22 [BirA] and HT22 [BirA/FLBIO-Klf9] cells is compared. The asterisks indicate statistically significant
differences analyzed by Student’s two-sample t-test (p < .005). e Klf9 associates with the same genomic loci in mouse hippocampus in vivo as in HT22
cells. Targeted chromatin immunoprecipitation (ChIP) assays for Klf9 were conducted on chromatin isolated from adult mouse hippocampus. The
asterisks indicate statistically significant differences from the normal goat serum (NGS) IgG control analyzed by Student’s two-sample t-test (p < .05)
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We conducted ChSP sequencing (ChSP-seq) on chro-
matin isolated from HT22 [BirA] and HT22 [BirA/
FLBIO-Klf9] cells to identify sites of Klf9 association in
chromatin. We used two independent peak calling pro-
grams (MACS and PePr) to identify genomic regions
with higher densities of mapped reads [24, 25]. MACS
analysis identified 8,841 peaks, while PePr analysis
identified 3,382 peaks present in HT22 [BirA/FLBIO-
Klf9] but not in HT22 [BirA] cells. All except four of
the peaks called by PePr were also called by MACS; the
peaks called by both programs were more enriched
(larger difference in the number of mapped reads in
HT22 [BirA/FLBIO-Klf9] compared to HT22 [BirA]
cells) than those called only by MACS (not shown). We
restricted further analysis to only those peaks called by
both programs (total = 3,378), and then applied the pro-
gram PeakSplitter to identify and subdivide regions
with multiple closely spaced peaks [26]. Peaksplitter is
only compatible with MACS; we therefore analyzed the
MACS dataset with Peaksplitter, then used the program
BedTools to extract the overlap of these split peaks
with the peaks called by PePr [27]. Examples of how
this approach classifies peaks are shown in Additional
file 4: Figure S3. This approach gave a final count of
3,514 Klf9 peaks, which ranged from 8 to 2,429 bp in
length (average length 881 bp). All peak coordinates,
nearest gene and average sequencing read density
across the peak (based on build mm10 of the mouse
genome) are given in Additional file 5: Table S2.
Sequencing and analysis of ChSP DNA from HT22
[BirA] cells showed very few regions (20 by MACS, 52
by PePr) with higher mapped sequencing read density
compared with HT22 [BirA/FLBIO-Klf9] cells. This
demonstrates that the BirA-FLBIO platform allowed for
identification of Klf9-associated genomic regions with
very low background.
Validation of Klf9 peaks identified by ChSP in HT22 cells
To validate the ChSP-seq dataset we analyzed 8 Klf9
peaks using targeted ChSP- and ChIP-qPCR assays. The
aligned sequencing read densities from the 8 genomic
regions are shown in Fig. 2c, with peaks arranged from
largest (220 overlapping reads at maximum height for
Slc11a2; upper left panel) to smallest (20 overlapping
reads for Mapk11; lower right panel). The small peak at
the Mapk11 5′ upstream region was detected by MACS
but not by PePr (see also Additional file 4: Figure S3);
we analyzed this region to investigate the lower limit of
detection of the ChSP-seq data set. All genomic regions
tested showed significantly higher signal with ChSP
DNA from HT22 [BirA/FLBIO-Klf9] cells compared
with HT22 [BirA] cells (Fig. 2d; Slc11a2: t (6) = −10.981,
p < .001; Klf16: t (6) = −14.417, p < .001; Klf13: t (6) =
−10.981, p < .001; Sin3a: t (6) = −10.135, p < .001; Nr3c1: t
(6) = −9.402, p < .001; Limk1: t (6) = −8.561, p < .001; Klf11: t
(6) = −8.653, p < .001; Mapk11: t (6) = −5.448, p < .005; n =
4/cell line; Student’s two-sample t-test). We also con-
ducted ChIP assay for Klf9 on chromatin extracted from
the parent HT22 cell line, which showed statistically sig-
nificant Klf9 ChIP signal (compared to IgG from normal
goat serum) at four genes tested (Additional file 6: Figure
S4; Klf16: t (4) = 6.285, p < .005; Limk1: t (4) = 4.093, p < .05;
Nr3c1: t (4) = 3.778, p < .05; Sin3a: t (5) = 3.159, p < .05;
n = 4/treatment; Student’s two-sample t-test). The Klf9
ChSP signal was at the background level at intronic
regions located 10 kb or more downstream from the
identified Klf9 peaks at the Klf16, Limk1 and Nr3c1
genes (Additional file 7: Figure S5A).
Klf9 associates in chromatin from mouse hippocampus
with genomic regions identified by ChSP-seq in HT22 cells
To determine if Klf9 associates in chromatin in mouse
hippocampus at genomic sites identified in HT22 [BirA/
FLBIO-Klf9] cells, we conducted targeted ChIP assays
using chromatin isolated from the hippocampal region of
the brain of adult wild type mice (five male and five
female). We analyzed the same 8 genomic regions de-
scribed above for HT22 cells and found statistically signifi-
cant Klf9 ChIP signal at 7 of the 8 regions in both males
and females (Fig. 2e; Slc11a2: t (13) = 2.260, p < .05; Klf16: t
(12) = .4.458, p < .001; Klf13: t (13) = 3.752, p < .005; Sin3a: t
(12) = 5.659, p < .0005; Nr3c1: t (10) = −2.684, p < .05; Limk1:
t (11) = 3.887, p < .005; Klf11: t (16) = 2.246, p < .05; Mapk11:
t (16) = −.0265, p = .979; n = 10; Student’s two-sample t-
test). Since there were no statistically significant differ-
ences between the sexes we pooled the data for analysis.
The lack of Klf9 ChIP signal at the 5′ upstream region of
Mapk11 is consistent with this region having the lowest
ChSP signal in HT22 [BirA/FLBIO-Klf9] cells (Fig. 2d).
We did not detect Klf9 ChIP signal in chromatin from
mouse hippocampus at intronic regions located 10 kb or
more downstream from the identified Klf9 peaks in the
Klf13, Klf16, Limk1 or Nr3c1 genes (Additional file 7:
Figure S5B). Taken together, our findings support that the
BirA/FLBIO platform applied to the HT22 cell line is a
useful model for identifying Klf9 genomic targets in
mouse hippocampus.
Klf9 associates in chromatin primarily with proximal
promoter regions
We used the ChIP-enrich web tool [28] to assign Klf9
peaks to genes based on the nearest transcription start site
(TSS), and to identify where the peaks were distributed
with respect to the TSSs of annotated genes. Based on this
analysis, 89.5% of the peaks fell within 10 kb of a TSS, and
of these, 86% (or 77.1% of total peaks) were 1 kb or less
from a TSS (Fig. 3a). The ChIP-enrich software assigns
peaks to genes based on the closest TSS, which results in
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some genes having multiple peaks associated with them.
After accounting for such double-counted targets, this left
2,847 genes with at least one associated Klf9 peak (defined
as being closer to that peak than any other annotated
gene). The majority of these genes (2,749) had at least one
Klf9 peak within 10 kb of their TSS.
We next used the HOMER peak annotation program
to analyze the distribution of Klf9 peaks relative to the
TSS. Of the peaks centered within 1 kb of a TSS, 32.7%
were centered upstream, 21.7% were centered within the
5′ untranslated region, and 27.1% were centered either
in the first exon or the first intron (Fig. 3b). We then
used the Cis-regulatory Element Annotation System
(CEAS) to map how sequencing reads were distributed
with respect to genomic features [29]. Analysis of the
distribution of mapped sequencing reads around TSSs
revealed a moderate bias towards regions immediately
upstream of the TSSs (Additional file 8: Figure S6).
Thus, the larger peaks tend to be centered in 5′ flanking
regions rather than in 5′ UTRs, exons or introns.
Of the 217 genes that we found to be repressed by
Klf9 by RNA-seq, 130 (60%) have a Klf9 peak within
10 kb of their TSS. By contrast, of the 21 genes found to
be induced by Klf9 only 1 (5%) had a peak within 10 kb
of its TSS (Fig. 3c). This is consistent with Klf9 acting
primarily as a transcriptional repressor. Differentially
regulated genes without associated Klf9 peaks may be in-
direct target genes (regulated by other Klf9-responsive
genes). If this is correct, it suggests that Klf9-induced
genes are mostly indirect targets, while the majority of
repressed genes are directly regulated by Klf9.
An additional 2,322 genes had at least one Klf9 peak
located within 10 kb of their TSS, but their mRNA levels
analyzed by RNA-seq were not significantly affected by
forced Klf9 expression. However, when we looked at the
mean mRNA level for all polyadenylated transcripts de-
tected by RNA-seq in the HT22 [TR/TO-Klf9] cell line
treated with vehicle or dox, and compared genes that
did or did not have Klf9 peaks within 10 kb of their TSS,
we found evidence for a general repressive action of Klf9
on transcription of genes possessing Klf9 peaks (Fig. 3d).
We calculated the ratio of the mean mRNA levels with
dox to that with vehicle for all expressed genes in each
of the two cell lines (“expression ratio”). An expres-
sion ratio of 1 indicates no change caused by dox
treatment, >1 indicates an increased mRNA level, and
<1 a decreased mRNA level. In comparing the expres-
sion ratio of genes with or without Klf9 peaks, we
found no statistically significant difference in the parent
cell line, but a statistically significant lower median
Fig. 3 Klf9 associates near transcription sites and is more likely to be associated with repressed than induced genes. a Distribution of Klf9 peaks
with respect to transcription start sites (TSS). b Distribution of Klf9 peaks with respect to gene features. c Overlap of Klf9-regulated genes with
genes containing Klf9 peaks within 10 kb of their TSS. d The median expression ratio of all genes expressed in HT22 cells, with or without
associated Klf9 peaks, in parent HT22 and HT22 [TR/TO-Klf9] cells treated with vehicle or doxycycline (1 μg/ml) for 8 h. In the parent cell line
there was no expression difference after dox treatment whether or not the genes have Klf9 peaks associated (within 10 kb of their TSS; p = .057;
Mann–Whitney U-test). In the HT22 [TR/TO-Klf9] cell line treatment with dox caused a statistically significant decrease in median expression ratio,
but only for genes with associated Klf9 peaks (p < .001; Mann–Whitney U-test)
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expression ratio for genes containing Klf9 peaks in the
HT22 [TR/TO-Klf9] cell line (Fig. 3d; parent line: p = .057;
HT22 [TR/TO-Klf9]: p < .001; Mann–Whitney U-test).
This supports that Klf9 exerts a general repressive action
on transcription of genes with which it associates.
Identification of consensus Sp/Klf motifs at regions of Klf9
ChSP-seq peaks
We used the program HOMER to identify enriched
DNA sequence motifs in Klf9 ChSP-seq peaks [30]. The
most highly enriched sequence was a Sp/Klf motif
(GCCACGCCCMCY) that was present in 75.6% of all
peaks; hereafter we refer to this sequence as the ‘Klf9
consensus motif ’ (Fig. 4a). We identified 18 additional
motifs enriched at Klf9 peaks that are partially redun-
dant with the Klf9 consensus motif. The top four most
frequently observed Sp/Klf motifs (found in >50% of all
peaks) are shown in Fig. 4a, and the remainder are
listed in Additional file 9: Table S3. The Klf9 consensus
motif, and the 18 additional motifs are hereafter col-
lectively referred to as Sp/Klf motifs. At least one Sp/
Klf motif was present in 98% of all Klf9 peaks, support-
ing that the presence of Sp/Klf motifs is important for
targeting Klf9 in the genome. In addition, HOMER
identified 18 significantly enriched motifs in Klf9 peaks
other than the Sp/Klf motifs, the most significantly
enriched of which (p < 1×10−20) matched previously re-
ported binding sites for early growth response 2 (Egr2),
ELK4, ETS transcription factor (Elk4), E2F transcription
factor 1 (E2f1), Fos-like 2 (Fosl2), basic helix-loop-helix
(bHLH), and regulatory factor X domain-containing 2
(Rfxdc2). A complete list of enriched motifs is given in
Additional file 10: Table S4.
The Klf9 consensus motif tended to occur at or near the
center of peaks, and the average density of mapped sequen-
cing reads across the peaks closely matched the frequency
of motif occurrence (Fig. 4b). The peaks contained between
0 and 19 Sp/Klf motifs (one outlier contained 48), with an
average of 4.47/peak. There was a weak but statistically
significant correlation between the number of non-
redundant Sp/Klf motifs and average peak height (Fig. 4c;
R = .245, p < .0001; Spearman Rank Order correlation).
We also used HOMER to analyze the promoters of
the 21 genes that were induced by Klf9. Sequences of
1000 bp in length located upstream of the TSSs of these
genes were downloaded from the UCSC genome
browser. Scanning these sequences for the presence of
Sp/Klf motifs found by de novo analysis of the Klf9
ChSP peaks found that only 4 of 21 (19%) contained
one copy of the Klf9 consensus motif, while 17 of 21
(81%) had at least one Sp/Klf motif.
Peak shape clustering reveals three separate categories
of Klf9 peaks
We analyzed Klf9 peaks using the program SIC-ChIP
[31], which clusters peaks into subcategories based on
five shape parameters (peak height, peak width at half-
maximum height, peak area, number of local subpeaks,
and shape index M (a measure of the peak’s topological


















Other Sp/Klf-like motifs present 
in >50% of all peaksKlf9 consensus motif
C
Fig. 4 Sp/Klf motifs are enriched at Klf9 peaks, they correlate with peak features, and they are required for transcriptional repression by Klf9. a Position
weight matrices showing the Klf9 consensus motif (left) and the four most commonly occurring Sp/Klf motifs that were partially redundant with the
consensus motif (right). b Histogram showing the probability of the Klf9 consensus motif occurrence (solid) and average enrichment (number of
mapped reads; dashed) across all Klf9 peaks. c Number of non-redundant Sp/Klf motifs correlates with the mean tag density across a peak
(R = .245, p = .0000002)
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distribution of each parameter in each cluster, and a
scatterplot of how shape parameters correlate with each
other and group peaks by cluster are shown in Additional
file 11: Figure S7. By these criteria we divided the peaks
into three categories, examples of which are shown in
Fig. 5a. Peaks in Cluster 1 (2115 peaks) are of low average
height and low complexity; peaks in Cluster 2 (812 peaks)
are of low height but greater complexity (as measured by a
higher M index and larger number of local subpeaks); peaks
in Cluster 3 (549 peaks) are large and of low complexity.









Fig. 5 Klf9 peaks group into shape clusters that show different likelihood of association with repressed genes, and degree of transcriptional
repression. a Klf9 peaks in HT22 cells can be grouped into three clusters based on shape and height characteristics. Example peaks from each
cluster are shown. The graph height (200 pixels on UCSC genome browser) and viewing window size (2 kb) are held constant. b Distribution of
the Klf9 consensus motif (top) and mapped sequencing read density (bottom) within peaks from each shape cluster. Sequencing read density
closely tracks the probability of the occurrence of consensus motifs in all clusters. c Average number of Sp/Klf motifs and number of Klf9
consensus motifs present in peaks belonging to each cluster. Boxplots indicate 75% and 25% quantiles; dots indicate 5% and 95% quantiles.
Means with the same letter are not significantly different (p < .05; Kruskal-Wallis non-parametric ANOVA). Top: peaks of clusters 2 and 3 contain
more Sp/Klf-like motifs than those of cluster 1; bottom: peaks of cluster 3 have more copies of the Klf9 consensus motif than peaks of clusters 1
and 2. d Percentage of peaks of each cluster associated with repressed genes. e Median ratio of mRNA levels in HT22 [TR/TO-Klf9] cells treated
+/− dox of genes associated with peaks from each cluster. Means with the same letter are not significantly different (p < .001; Kruskal-Wallis
non-parametric ANOVA)
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The Klf9 consensus motif was highly enriched in peaks
from all three categories. In genomic regions defined by
Clusters 1 and 3, the motifs were located near the center of
the peak, while in Cluster 2 the distribution was spread
evenly across the peak (Fig. 5b, upper panel). The density of
mapped reads (reflective of peak height) closely matched
the distribution of Klf9 consensus motifs in all three clusters
(Fig. 5b, lower panel). Sequencing read density (peak height)
therefore correlates with the presence of Klf9 consensus
motifs, even in wide peaks with multiple local maxima such
as those seen in cluster 2. Clusters 2 and 3 had a larger
number of Sp/Klf motifs per peak than Cluster 1 (Fig. 5c,
upper panel; H (2) = 528.802, p < .001; Kruskal-Wallis non-
parametric ANOVA). There was no significant difference
between Clusters 2 and 3 in average number of Sp/Klf
motifs, but peaks from Cluster 3 contained more copies of
the Klf9 consensus motif (Fig. 5c, lower panel; H (2) =
245.055, p < .001; Kruskal-Wallis non-parametric ANOVA).
The proportion of peaks associated with Klf9-repressed
genes differed among clusters, with Cluster 3 having the
highest percentage, and Cluster 1 the lowest (Fig. 5d). This
supports that large peaks with larger numbers of Sp/Klf
and Klf9 consensus motifs are more likely to be associated
with genes that are repressed by Klf9. In further support
of this observation, the distribution of peaks from each
cluster associated with repressed genes was nonrandom.
Peaks from Cluster 1 accounted for 60.1% of all peaks,
and 35% of repressed genes had at least one peak from
Cluster 1 associated. In contrast, while peaks from
Clusters 2 and 3 accounted for 23.1 and 15.6% of all peaks,
respectively, 20.3 and 23% of all repressed genes had a
peak from Clusters 2 or 3 associated (Additional file 12:
Figure S8). Peaks from Clusters 2 and 3 are therefore
more likely to be associated with repression by Klf9 than
would be expected by chance (Chi-Square = 28.704 with 2°
of freedom, p < .001).
We also calculated the expression ratio of genes with
peaks from each cluster in vehicle vs. dox-treated HT22
[TR/TO-Klf9] cells. Genes with peaks from Cluster 2 show
a lower expression ratio (indicating greater repression) than
genes with peaks from Cluster 1, and genes with peaks
from Cluster 3 have a lower expression ratio than from
Cluster 2, supporting that Klf9 exerts a stronger repres-
sive effect on transcription from peaks with either a
greater number of consensus motifs or a higher ChSP
signal (Fig. 5e; H (2) = 45.181, p < .001; Kruskal-Wallis
non-parametric ANOVA).
Genomic regions where Klf9 associates support
transcriptional repression by Klf9, and this requires intact
Sp/Klf motifs
To determine if Klf9 can repress transcription of genes with
which it associates in chromatin we transfected HT22 [TR/
TO-Klf9] cells with pGL4.23 reporter constructs containing
DNA fragments corresponding to genomic regions with
Klf9 ChSP peaks: Klf13 (439 bp; 6 Sp/Klf motifs, of which 3
were Klf9 consensus), Klf16 (2192 bp; 17 Sp/Klf motifs, of
which 6 were Klf9 consensus), Limk1 (802 bp; 11 Sp/Klf
motifs, of which 4 were Klf9 consensus) and Mapk11
(886 bp; 6 Sp/Klf motifs, of which zero were Klf9 consen-
sus) (see Additional file 4: Figure S3 for the ChSP peaks
determined by PePr and the relative locations of the cloned
DNA fragments, and Additional file 13: Table S5 for the
DNA sequences and locations of Sp/Klf motifs within
them). Treatment with dox for 24 h reduced luciferase ac-
tivity from pGL4.23-Klf13 by 33%, pGL4.23-Klf16 by 45%,
and pGL4.23-Limk1 by 19.5%; luciferase activity from the
pGL4.23-Mapk11 vector was unaffected by dox treatment
(Fig. 6; Klf13: t (10) = 8.512, p < 10
−5; Klf16: t (10) = 4.430,
p < .005; Limk1: t (10) = 3.275, p < .01; Mapk11: t (9) = 1.509,
p = .166; Klf13 mutant: t (10) = −1.331, p = .213; n = 6/
treatment; Student’s two-sample t-test).
Fig. 6 Klf9 represses transcription from synthetic promoters of Klf9 target genes, and Sp/Klf-like motifs are required for transcriptional repression by
Klf9. We transfected HT22 [TR/TO-Klf9] cells with reporter constructs containing cloned DNA fragments corresponding to genomic regions with Klf9
peaks associated with the indicated genes (See Additional file 4: Figure S3 for genomic ranges). Forced expression of Klf9 repressed transcriptional
activity from the Klf13, Klf16 and Limk1, but not from the Mapk11 promoter. Mutation of six Sp/Klf-like motifs in the Klf13 promoter abrogated
Klf9-dependent repression. The asterisks indicate a statistically significant difference from control by Student’s two-sample t-test (p < .01)
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To determine if Sp/Klf motifs are required for repres-
sion by Klf9 we focused on the Klf13 5′ flanking region,
which contains 6 Sp/Klf motifs (Additional file 13: Table
S5). We used site-directed mutagenesis to convert these
motifs to a series of 7 thymidines; the complete se-
quence of the Klf13 DNA fragment and the location of
the mutated nucleotides are given in Additional file 13:
Table S5. Mutation of two of the 6 Sp/Klf motifs (sites 4
and 5), either individually or in combination, did not
affect repression by Klf9 (data not shown). However,
mutation of all six sites abolished Klf9-dependent tran-
scriptional repression (Fig. 6).
Forced expression of Klf9 promotes recruitment of Sin3a
to some genomic regions with Klf9 peaks
Our RNA-seq experiment showed that Klf9 acts predom-
inantly as a transcriptional repressor in HT22 cells. The
N-terminus of Klf9 has a motif for interaction with the
scaffolding repressor protein Sin3a [33] which recruits
histone deacetylases to generate a compact chromatin
structure and transcriptional repression. We therefore in-
vestigated whether Sin3a was recruited to Klf9 peaks by
conducting ChIP assay for Sin3a on chromatin isolated
from HT22 [TR/TO-Klf9] cells treated with vehicle or
dox for 12 h. Treatment with dox increased the mean
Klf9 ChIP signal at eight genomic regions correspond-
ing to Klf9 ChSP peaks; this increase was statistically
significant for six of the eight peaks (Additional file 14:
Figure S9A). There were statistically significant in-
creases in Sin3a ChIP signal following dox treatment at
the Klf16, Sin3a, Nr3c1 and Limk1 genes, but it was un-
changed at Slc11a2, Klf13 and Klf11, and was reduced
at Mapk11 (Additional file 14: Figure S9B; Slc11a2: t (7) =
−4.628, p < .005; Klf16: t (8) = −4.628, p < .005; Klf13: t
(10) = −2.829 p < .05; Sin3a: t (9) = −2.138, p = .06; Nr3c1:
t (10) = −2.684, p < .05; Limk1: t (8) = −2.334, p < .05; Klf11: t
(7) = −2.371, p < .05; Mapk11: t (6) = −2.299, p = .06.; n = 6/
treatment; Student’s two-sample t-test).
Depletion of Klf9 leads to dysregulation of Klf9 target
genes
To determine if loss of Klf9 alters the expression of
Klf9 target genes we used CRISPR/Cas9 genome editing
to generate Klf9 knockdown (CRISPR line 1) and
knockout (CRISPR line 2) HT22 cell lines. A descrip-
tion of the mutations introduced into these cell lines is
given in Additional file 15: Table S6. The CRISPR line 1
exhibited significantly higher mRNA levels compared to
wild type for all Klf9-repressed genes analyzed except
Mapk11 (Fig. 7a; Slc11a2: F (2,12) = 9.091, p < .005; Klf13: F
Fig. 7 Klf9 target genes are dysregulated in Klf9 HT22 depleted cells and in Klf9 knockout mice, and depletion of Klf9 accelerates the cell cycle in
HT22 cells. a Klf9 target genes are dysregulated in HT22 cells with Klf9 depleted by CRISPR/Cas9 genome editing. Asterisks indicate a statistically
significant difference from the parent HT22 cell line (p < 0.05; ANOVA followed by Holm-Sidak post-hoc test). b Klf9 target genes are dysregulated
in the hippocampus of postnatal day 7 Klf9-null mice. Asterisks indicate a statistically significant difference from wild-type mice by Student’s two-
sample t-test (p < .05). c Cells with Klf9 depleted by CRISPR/Cas9 genome editing showed a higher percentage of cells in M phase (gray bars,
lowercase letters) and a lower percentage in G1/G0 phase (black bars, uppercase letters). Means with the same letter are not significantly different
(p < .05; ANOVA followed by Holm-Sidak post-hoc test). d The mRNA levels for two Klf9 target genes involved with cell cycle control are increased
in Klf9 mutant HT22 cells. Means with the same letter are not significantly different (p < .05; ANOVA followed by Holm-Sidak post-hoc test)
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(2,12) = 14.267, p < .001; Klf16: F (2,13) = 14.135, p < .001;
Limk1: F (2,13) = 5.875, p < .05; Klf11: F (2,11) = 9.1, p < .01;
Mapk11: F (2,13) = .922, p = .422; n = 6/cell line; ANOVA).
The CRISPR line 2 also had higher mean mRNA levels for
all genes analyzed (again, except for Mapk11) and this was
statistically significant for Klf13, Limk1 and Klf11.
We also analyzed mRNA levels for a subset of Klf9
target genes identified in HT22 cells in the hippocam-
pus of Klf9-null mice. Klf9 mRNA in the mouse CNS is
low at birth, then rises during the first 4 weeks of life,
paralleling the postnatal rise in plasma TH concentration
[34]. The mRNAs for Klf13, Limk1, Apc2 and Nlgn2 were
dysregulated at PND7 in Klf9-null mice, although the
direction of change differed among the genes (Fig. 7b;
Klf13: t (5) = −3.785, p < .01; Limk1, t (5) = −2.763, p < .05;
Mapk11: t (4) = 2.777, p = .05; n = 4 animals/genotype;
Student’s two-sample t-test). Mapk11 mRNA was not
different between wild type and Klf9-null mice. These ex-
pression differences disappeared by PND14 and remained
unchanged at PND 60 (data not shown).
Gene ontology analysis supports roles for Klf9 in
neuronal morphology and function
We conducted gene ontology (GO) and pathway ana-
lysis using GeneCoDis on Klf9-repressed genes (Table 2)
[35–37]. Four GO: PANTHER pathways were enriched
among Klf9-repressed genes: “Cytoskeletal regulation
by Rho GTPase”, “Inflammation mediated by chemokine
and cytokine signaling pathway”, “Wnt signaling pathway”,
and “B Cell Activation” (Table 2). We excluded the Klf9-
induced genes from the pathway analysis because of the
small number discovered and because we were able to val-
idate only 3 of 6 tested.
We then conducted pathway analysis on the set of all
genes with Klf9 ChSP peaks. The most enriched PANTHER
pathways among this set of genes were “Apoptosis”,
“Integrin signaling pathway”, “Inflammation mediated
by chemokine and cytokine signaling pathway” and
“Cytoskeletal regulation by Rho-GTPase” (Table 2
and Additional file 16: Table S7). The overlap with
the categories enriched among Klf9-repressed genes
supports an important role for Klf9 in these path-
ways. We also conducted separate analyses on the
genes with peaks of different shape clusters associ-
ated (see above). The top PANTHER pathways
enriched in genes associated with Cluster 1 peaks were
“Apoptosis”, “Wnt signaling pathway” and “Egf recep-
tor signaling pathway”. In contrast, the top pathways
enriched in the set of genes associated with Cluster 2
peaks were “Cytoskeletal regulation by Rho GTPase”
and “Metabotropic glutamate receptor group II pathway”,
while Cluster 3 peaks were associated with genes in
the pathways “PDGF signaling”, “Fas signaling path-
way” and “Cytoskeletal regulation by Rho GTPase”
(Additional file 17: Table S8).
Table 2 Genes repressed by forced Klf9 expression in HT22 [TR/TO-Klf9] cells and genes with Klf9 peaks associated in HT22 [BirA/
FLBIO-Klf9] cells were subjected to pathway analysis using GeneCoDis
Panther ID Pathway Number of Klf9 target
genes in pathway
Adjusted p value
All enriched pathways among genes repressed by Klf9
Panther:P00016 Cytoskeletal regulation by Rho GTPase 3 0.034087
Panther:P00031 Inflammation mediated by chemokine and cytokine signaling pathway 5 0.041865
Panther:P00057 Wnt signaling pathway 5 0.041865
Panther:P00010 B cell activation 3 0.046343
The top ten most enriched pathways among genes with Klf9 peaks associateda
Panther:P00006 Apoptosis signaling pathway 31 8.67E-11
Panther:P00034 Integrin signalling pathway 36 2.79E-10
Panther:P00031 Inflammation mediated by chemokine and cytokine signaling pathway 46 3.16E-10
Panther:P00016 Cytoskeletal regulation by Rho GTPase 23 1.28E-09
Panther:P00005 Angiogenesis 33 1.51E-09
Panther:P00057 Wnt signaling pathway 42 1.75E-08
Panther:P00056 VEGF signaling pathway 19 2.64E-08
Panther:P00047 PDGF signaling pathway 28 2.82E-08
Panther:P04393 Ras Pathway 20 7.85E-08
Panther:P00021 FGF signaling pathway 24 4.71E-07
Pathways are ordered from most- to least-enriched based on the false discovery rate (FDR)-adjusted p value
a A complete list of enriched pathways is given in Additional file 16: Table S7
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Depletion of Klf9 shortens cell cycle in HT22 cells and
de-represses genes involved in cell proliferation
Previous work showed that Klf9 can reduce proliferation
of different cell types [38–40]. One of the top GO: PAN-
THER pathways enriched among Klf9-repressed genes
was ‘Wnt signaling’. The Wnt pathway has been shown
to increase cell proliferation in diverse tissue types, in-
cluding in neurons [41, 42]. We therefore looked at
whether the cell cycle was altered in Klf9-deficient
HT22 cells using flow cytometry. To facilitate our ability
to observe differences in the cell cycle we cultured cells
in reduced serum (2% vs. 10%; see Methods). We found
that both CRISPR cell lines had a significantly higher
proportion of cells in M phase (and a lower proportion
in G1/G0) compared with the parent HT22 cell line
(Fig. 7c; G1/G0 (lowercase): F (2,8) = 56.27, p < .001; M
(uppercase): F (2,8) = 408.754, p < .001; n = 4/cell line;
ANOVA). The mRNA levels for two confirmed Klf9 tar-
gets that are classified as Wnt-pathway related and are
implicated in promoting mitosis, B cell CLL/Lymphoma
6 (Bcl-6) and inositol triphosphate receptor 3 (Itpr3),
were significantly elevated in both CRISPR lines (Fig. 7d;
Bcl-6: F (2,9) = 19.797, p = 0.001; Iprt3: F (2,9) = 13.346,
p = 0.002; n = 6/cell line; ANOVA).
Discussion
Here we report the first genome-wide analysis of Klf9
genomic targets in a mammalian neuronal cell type. Klf9
has been implicated in several aspects of neural devel-
opment and regeneration, and is regulated by hormones
[5, 7, 9, 10, 18], NFκB [7], oxidative stress [43], and
electrical activity [16]. We therefore set out to identify
its genomic targets in neurons to understand how it
mediates transcriptional responses to these stimuli,
and regulates neuronal differentiation, survival and
plasticity. We identified Klf9-regulated genes and
genomic regions where Klf9 associates in chromatin
using the mouse hippocampus-derived neuronal cell
line HT22. We show that Klf9 functions primarily as
a transcriptional repressor, that it associates in chro-
matin predominantly near TSSs, and that it regulates
transcription of genes involved in cytoskeletal remod-
eling, Wnt signaling and inflammation, among other
pathways. Furthermore, by analyzing a subset of the
genes and genomic regions identified in HT22 cells,
we verified that these genes are bona fide Klf9 targets
in mouse hippocampus in vivo, supporting that the
HT22 cell line represents a useful model for mature
hippocampal neurons, at least for the purpose of
identifying candidate Klf9 target genes. Taken together,
our findings represent an important advance in un-
derstanding the diverse developmental and physio-
logical roles that Klf9 has in the mammalian central
nervous system.
Klf9 acts as a transcriptional repressor through
association with proximal promoter regions
Findings from our RNA-seq experiment conducted in
HT22 cells support that Klf9 acts predominately as a tran-
scriptional repressor, with 10 times more genes repressed
than induced. This is consistent with a recent study in
glioblastoma cells that showed that Klf9 functions pri-
marily as a transcriptional repressor [40]. Of the 10
Klf9-repressed genes that we attempted to validate by
RTqPCR, we were able to confirm 9. However, of the 6
Klf9-induced genes tested by RTqPCR, we could valid-
ate only 3 (see Fig. 1e). Induction of these genes by
Klf9 was transient, with all 3 genes returning to base-
line by 24 h following dox treatment. By contrast,
mRNA levels of 7 of the 9 validated repressed genes
remained low at 24 h.
Using ChSP-seq we found that Klf9 associates predom-
inantly with genomic regions within 1 kb of TSSs. Genes
found to be repressed by Klf9 by RNA-seq were much
more likely than induced genes to have Klf9 associated in
chromatin (i.e., 60% of repressed genes had Klf9 associ-
ated, but only 5% of induced genes had Klf9 associated
with their genomic regions). These findings support that
Klf9 represses gene transcription by associating in chro-
matin at or near proximal promoters. In support of this,
the presence of Klf9 at proximal promoter regions was
associated with weak repression when averaged across all
genes with peaks associated (see Fig. 3d). Because only
one of the genes induced by Klf9 had a peak associated
and the induced genes showed only transient induction,
or failed to validate by RTqPCR, we conclude that they
are either false positives or indirect targets of Klf9. Import-
antly, we found that of 10 peaks investigated, 9 had Klf9
associated with them in chromatin isolated from adult
mouse hippocampus. This supports that HT22 cells can
be used as a model to identify potential Klf9 genomic tar-
gets in adult mouse hippocampus, and to investigate Klf9
function in chromatin in mature neurons.
Klf9 association in chromatin is strongly correlated with
the presence of Sp/Klf motifs
The most enriched motif in Klf9 peaks was an Sp/Klf
motif (GCCACGCCCMCY) that was present in 75% of
all peaks; furthermore, 98% of all peaks had at least one
Sp/Klf motif that was similar to the consensus motif.
The consensus motif tended to occur near the center of
peaks and its position correlated with the density of
mapped reads, supporting that Klf9 binds directly to
these DNA sequences.
Early studies on Klf9 function showed that it could act
as a transcriptional activator or repressor depending on
the number of Sp/Klf motifs present in the regulatory
element [2, 3]. In CV-1 cells, Klf9 activated transcription
from promoters containing multiple Sp/Klf motifs, but
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repressed transcription from promoters containing a sin-
gle Sp/Klf motif. Most Klf9 peaks in HT22 cells (88%) had
more than one Sp/Klf motif, but Klf9 acted almost
exclusively as a repressor, suggesting that its regula-
tory activity is not necessarily related to the number
of Sp/Klf motifs present. Other studies have shown
that Klf9 can activate or repress the same promoter
in the same cell type depending on the developmental
stage [44]. The chromatin environment and the comple-
ment of interacting proteins may be more important than
the promoter sequence for determining whether Klf9 acts
as an activator or repressor.
An additional Sp/Klf-like motif different from the Klf9
consensus motif was present in 14.84% of peaks (Additional
file 10: Table S4). This motif most closely matches the
binding site for Sp1, which typically acts as a transcrip-
tional activator [45]. Thus, the relative concentrations of
Klf9, which likely acts as a repressor, and Sp1 in the cell
may determine the transcriptional activity from these loci
[46]. However, it is also possible that these are binding
sites for other Sp/Klf proteins (including Klf9), which may
act as repressors or activators of transcription.
Seventeen other enriched motifs similar to known TF
response elements were identified by HOMER in Klf9
peaks (Additional file 10: Table S4). Several of these motifs
are response elements for TFs important for neuronal
structure and function. For example, two of the motifs in
this list match binding sites for members of the immediate
early gene families Egr and Fos (present in 28.55% and
21.21% of peaks respectively), which are involved in neural
activity-dependent transcription [47]. Klf9 is also induced
by neural activity [16], and thus may modulate the activity
of these TFs, or vice versa, when recruited to common
genomic regions..
Another enriched motif (present in 24.31% of peaks)
was the E-box. The E-box is required for transcriptional
activation by the core circadian transcription factors
CLOCK and Bmal1, which form a regulatory feedback
loop with Per and Cry proteins to orchestrate circadian
rhythms in most tissues [48–51]. Several Klf genes have
been found to exhibit circadian oscillations in their ex-
pression, including Klf9 [52]. Klf9 mediates circadian
variation in cell proliferation in keratinocytes [38], but
to our knowledge its role in circadian physiology in
other tissues has not been investigated. One of the GO:
PANTHER pathways enriched among genes with Klf9
peaks is “Circadian Clock System” (Additional file 16:
Table S7). This suggests that Klf9 may co-regulate
CLOCK/Bmal1 target genes, and thus modulate the core
loop of the cellular circadian clock. While other Klfs
have been shown to function as clock-output genes to
orchestrate circadian physiology [53, 54], no Klfs have
been shown to directly participate in the CLOCK/Per
regulatory loop.
Clustering analysis provides a basis for differentiating
peaks associated with repressed genes
Different types of chromatin-associated proteins have dif-
ferent ChIP-seq profiles (e.g. broad regions for histones,
discrete regions for TFs) and different genomic regions as-
sociated with the same factor may have different peak
shapes [31]. We found that Klf9 peaks could be divided
into three groups. Large, sharp peaks (Cluster 3) or
broad, complex peaks (Cluster 2) were more likely to
be associated with genes repressed by Klf9 than were
smaller, less complex peaks (Cluster 1). In addition, the
genes associated with Cluster 3 peaks were on average
more strongly repressed after dox treatment on HT22
[TR/TO-Klf9] cells (see Fig. 5e).
The different peak characteristics could reflect at
least three basic mechanisms: different numbers of Klf9
molecules recruited, perhaps related to the number of
Sp/Klf motifs; differences in the chromatin environment
(i.e., nucleosome density and histone modifications) that
modulates accessibility of the locus; or local differences in
the presence of protein interacting partners that may
stabilize Klf9 association at the region. Peaks from Clus-
ters 2 and 3 had more Sp/Klf motifs than peaks from
Cluster 1 (Fig. 5c), which is consistent with recruitment of
more Klf9 molecules as measured by height and area
under the curve (Additional file 7: Figure S5C and D).
Cluster 3 peaks had the same average number of Sp/Klf
motifs as Cluster 2 peaks, but they had more copies of the
Klf9 consensus motif (Fig. 5c); the high, sharp signal at
these loci could reflect a higher affinity for Klf9 binding to
the Klf9 consensus motif leading to more Klf9 association.
Alternatively, or in addition, the chromatin environment
at these regions may be more accessible, and/or there is
greater recruitment of Klf9 interacting proteins that leads
to increased crosslinking efficiency. Whether the peak
characteristics result in differences in the kinetics and/or
magnitude of transcriptional regulation of the associated
genes requires investigation.
Repression by Klf9 requires intact Sp/Klf motifs
To determine if the genomic regions where Klf9 associ-
ates are capable of supporting transcriptional repression,
we isolated and subcloned several DNA fragments corre-
sponding to peaks identified by ChSP-seq that were lo-
cated in the 5’ upstream regions of Klf9-responsive
genes. Forced expression of Klf9 repressed transcrip-
tional activity supported by the Klf13, Limk1 and Klf16
upstream regions, but not by Mapk11. For the Klf13
promoter we showed that Sp/Klf motifs are required for
Klf9-dependent transrepression. Although the Mapk11
region has five predicted Sp/Klf-like motifs, it lacks any
copies of the Klf9 consensus motif. By contrast, the
Klf13, Limk1 and Klf16 upstream regions that we investi-
gated have 3, 4 and 6 Klf9 consensus motifs,
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respectively. Based on these findings we hypothesize that
the Klf9 consensus motif is essential for mediating Klf9-
dependent repression. The presence of multiple Sp/Klf
motifs at most Klf9 peaks implies that such redundancy
may be a feature of many, if not most, Klf9 genomic tar-
gets. These sites could also potentially act as binding
sites for other Sp or Klf-like proteins, which suggests the
potential for combinatorial regulation by a network of
Klfs [55].
Cellular pathways targeted by Klf9 in HT22 cells
To evaluate cellular pathways regulated by Klf9 in
HT22 cells we analyzed GO: PANTHER enriched path-
ways among Klf9-repressed genes identified by RNA-
seq, and also enriched pathways among genes with Klf9
peaks identified by ChSP-seq. The most enriched GO:
PANTHER pathway among Klf9-repressed genes was
“Cytoskeletal Regulation by Rho-GTPase”. This path-
way was number 4 on the list of enriched pathways
among Klf9 bound genes (see Table 2). Among the
Klf9-regulated genes in this category are Limk1, which
has been shown to promote neurite extension through
inhibition of actin depolymerization [56], and Mapk7
(ERK5), which positively regulates neurite extension
and arborization in hippocampal neurons [57]. Several
genes involved in actin polymerization, such as Limk1,
were direct genomic targets of Klf9. The repression of
positive regulators of actin polymerization such as
Limk1 is consistent with published findings showing
that Klf9 represses dendritic and axonal remodeling
and outgrowth in mature neurons [13, 14]. However,
this does not explain how Klf9 promotes neurite elabor-
ation and outgrowth in immature neurons [8, 12]. It
may regulate a different set of genes, perhaps repressing
repressors of growth, or it may upregulate rather than
repress the same loci identified in this study at earlier
developmental stages [44].
The second most enriched pathway for Klf9-repressed
genes was “Inflammation mediated by chemokine and
cytokine signaling pathway”, and this pathway was num-
ber 2 on the list of Klf9 bound genes. Several other Klfs
have been implicated in immune and inflammatory re-
sponses [58]. For example, Klf4 promotes differentiation
of monocytes and directly upregulates transcription of
the pro-inflammatory cytokine interleukin-6 [59–62]. It
also cooperates with the glucocorticoid receptor to in-
duce expression of anti-inflammatory genes in keratino-
cytes [63]. Klf13 regulates expression of IL-4 in CD4 (+)
T cells [64]. Klf10 has been found to regulate TGF-beta
signaling in CD8 (+) T lymphocytes through modulating
expression of TGF-beta receptor type II expression [65].
In contrast, Klf2 generally has anti-inflammatory actions
[66]; for example, it inhibits inflammatory activation of
monocytes through inhibition of the transcriptional
activity of NF-κB [67] and blocks CD4 (+) T follicular
helper cell differentiation [68]. However, Klf2 has also
been shown to be required for activation of vascular
endothelial cells in response to proinflammatory factors
[69]. Klf6 has been shown to function as an accessory
transcription factor for NF-kappa B [70]. To our know-
ledge, there have been no reports linking Klf9 to
inflammatory signaling. However, Klf9 is induced by
glucocorticoids in mouse macrophages [71] and in neu-
rons [7, 11, 18] via conserved glucocorticoid response
elements [7, 18]. The repressive activity of Klf9 may
serve as a counterbalance to pro-inflammatory Klfs
such as Klf4, allowing for modulation of the immune
response. It is also noteworthy that the Klf9 Synergy
Module, which is an ultraconserved enhancer element lo-
cated 4–6 kb upstream of the TSSs of tetrapod Klf9 genes,
contains a NFkB site to which P50 associates, and LPS
can modulate Klf9 expression in HT22 cells [7].
The top enriched cellular pathway for genes with Klf9
ChSP peaks was apoptotic signaling. Interestingly, these
genes are most strongly associated with peaks from
Cluster 1; whereas, peaks from Clusters 2 and 3 are
enriched in cytoskeletal and growth factor-related path-
ways, respectively (see Additional file 17: Table S8). Genes
with peaks from Clusters 2 and 3 were more likely to be
repressed by 8 h of dox treatment than genes from Cluster
1. If the kinetics and/or magnitude of transcriptional regu-
lation varies among genes from the different peak clusters,
with genes from Cluster 1 exhibiting slower kinetics than
genes from Clusters 2 and 3, then one can propose the
following model: Rapid induction of Klf9 (e.g., in response
to an acute stressor) suppresses morphological remodeling
and cell proliferation by direct repression of a set of ‘first
tier’ target genes (from Clusters 2 and 3). On the other
hand, prolonged induction of Klf9 in response to chronic
stress may promote repression of anti-apoptotic genes and
induction of pro-apoptotic genes (Cluster 1 peaks or
‘second tier’ targets), leading to cell death. This model
might be supported by findings of a role for Klf9 in pro-
moting cell death in response to chemotherapeutics and
oxidative stress [43, 72].
Depletion of Klf9 in HT22 cells leads to de-repression of
Klf9 target genes
Knock-down or knock-out of Klf9 in HT22 cells using
CRISPR/Cas9 genome editing caused dysregulation of
several Klf9 target genes. The genes Klf13, Klf16 and
Limk1 were repressed by forced Klf9 expression, but
were increased in Klf9 deficient HT22 cells, supporting
a direct role for Klf9 in regulating transcription of these
genes. The genes Slc11a2 and Klf11 were not repressed
by forced Klf9 expression, but their mRNAs were in-
creased following Klf9 depletion, and both genes had
Klf9 peaks. Mapk11 did not show any change in
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expression in CRISPR knockout cells despite its weak
repression by forced Klf9 expression and the presence
of a Klf9 peak at its proximal promoter region. The
Klf9 peak at Mapk11 was at the lower limit of detection
by ChSP-seq (in fact, it was detected by the MACS al-
gorithm, but not by PePr). ‘Weak’ peaks such as this may
represent genes that are regulated under conditions of
high Klf9 expression, but are not dependent on Klf9 for
controlling baseline expression.
Despite the changes seen in HT22 cells, few differences
in target gene mRNA level were seen in Klf9 KO mice
compared to age-matched wild-type animals, and what
differences did exist tended to disappear after the first
postnatal week (not shown). This suggests that there are
compensatory mechanisms for regulating baseline mRNA
levels in the absence of Klf9. The Klf family members 3, 5,
7, 10, 12, 13, 14 and 16 are all expressed in the adult
mouse hippocampus, based on in situ hybridization data
provided in the Allen Brain Atlas [73]. Some or all of these
may contribute to compensatory regulation in the absence
of Klf9. Functional compensation between Klfs has been
demonstrated in embryonic stem cells, in which Klfs 2, 4
and 5 form a partially redundant network that maintains
pluripotency. Knockout of all three is required to induce
differentiation into fibroblasts [55]. Klf13, 14 and 16 are
the Klf family members most similar to Klf9 and are there-
fore the most likely candidates for compensating for loss
of Klf9 in the hippocampus [1]. In the mouse uterus Klf9
and Klf13 have partially overlapping functions such that
Klf9 can partially compensate for the absence of Klf13
[74]. We found that Klf9 associates with and represses
transcription from the promoters of Klf13 and Klf16 in
HT22 cells and associates with these genes in the mouse
hippocampus in vivo. To our knowledge this is the first
evidence of repression of direct cross-regulation between
Klf9 and Klf13 and supports that these Klf proteins may
regulate each other’s expression as well as activating or
repressing shared targets. Investigation of the Klf13 and
Klf16 cistromes in HT22 cells and the mouse hippocam-
pus will be important to shed further light on the extent
of cooperation or antagonism among Klf9, Klf13 and
Klf16 in neurons.
A role for Klf9 in modulation of the cell cycle in HT22 cells
Previous studies showed that Klf9 can suppress cell
proliferation and/or promote apotosis [40, 72]. Consist-
ent with these findings, we found that knockdown or
knockout of Klf9 shortened the cell cycle in HT22 cells
and increased expression of genes involved in cell pro-
liferation. The Klf9-repressed genes Bcl-6 and Itpr3 are
part of the Wnt signaling pathway. Bcl-6 was shown to
suppress apoptosis through induction of cyclin d1, and
is sufficient to immortalize mouse embryonic fibro-
blasts [75]. In a human breast cancer cell line (MCF-7)
knockdown of Itpr3 caused cell cycle arrest, supporting
that it is important for promoting tumor proliferation
[76]. Furthermore, Itpr3 can confer resistance to apoptosis
[77]. The increase in expression of these two genes, and
possibly other genes involved in cell proliferation and sur-
vival, may underlie the increase in cell proliferation that
we observed after depletion of Klf9 in HT22 cells. This
would be consistent with reports that Klf9 can act as a
tumor suppressor and promote apoptosis in response to
chemotherapeutics [39, 40, 72].
Conclusions
We provide the first unbiased analysis of Klf9 genomic
targets in mouse hippocampal neurons. We also provide
strong evidence for a cross-regulatory network of Klfs
that may be important for regulating the transcriptome.
Our findings establish a foundation for understanding
the molecular basis for Klf9’s effects on neuronal morph-
ology and cell proliferation. Finally, we demonstrate the
utility of HT22 cells for identifying genomic targets of
TFs in the mouse hippocampus.
Methods
Plasmids
We obtained the HT22 cell line from Dr. David Schubert,
the Salk Institute, La Jolla, CA. To engineer HT22 cells
lines for controlled Klf9 expression we used the pRSV-
BTEB plasmid (gift of Dr. Fuji-Kuriyama) as template to
PCR-amplify the full-length Klf9 cDNA. We then
directionally cloned the cDNA into the pCDNA4:TO
(Invitrogen) and pEF1α-FLBIO (gift of Jianlong Wang;
Kim et al., 2009) expression vectors at the XhoI/XbaI
(pCDNA4:TO) or BamhI/XbaI (pEF1α-FLBIO) sites. To
construct a vector to express the biotin ligase BirA we
used the pEF1α-BirA plasmid (gift of Jianlong Wang)
(Kim et al., 2009) as template to PCR-amplify a DNA frag-
ment containing the EF1α promoter, the BirA coding se-
quence and the polyadenylation sequence. We subcloned
this DNA fragment into the pSV40 zeocin plasmid (gift of
Dr. Michael Uhler) at the NotI and NheI sites. Note that
HT22 cells are resistant to G418 and the pEF1α-BirA
plasmid has a neomycin cassette, so we needed to move
the BirA sequence to a plasmid containing a different anti-
biotic resistance gene (zeocin). To express Klf9 in transi-
ent transfection assays we used pCS2-Klf9 [78].
We constructed a reporter plasmid (pGL4.23-3xBTE)
containing three tandem repeats of the Basic Transcrip-
tion Element (BTE) [2] by synthesizing complementary
oligonucleotides and ligating the duplex oligonucleotide
into pGL4.23 (Invitrogen, Carlsbad, CA) at the HindIII
and NheI sites. We isolated the 5′ flanking regions of
Klf13 (439 bp), Limk1 (800 bp), Klf16 (2200 bp), and
Mapk11 (887 bp) by PCR using genomic DNA isolated
from HT22 cells as template (the genomic DNA was
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isolated using the DNEasy DNA extraction kit (Qiagen,
Hilden, Germany) according to manufacturer’s instruc-
tions) and subcloned the DNA into pGL4.23 at the SacI/
HindIII, NheI/KpnI, NheI/HindIII, or SacI/XhoI sites to
create pGL4.23 [Klf13] promoter, pGL4.23 [Limk1] pro-
moter, pGL4.23 [Klf16] promoter and pGL4.23 [Mapk11]
promoter, respectively.
Using the pGL4.23 [Klf13] promoter plasmid as template,
we conducted site-directed mutagenesis of predicted Sp/Klf
motifs using the Quikchange kit (Agilent Technologies,
Santa Clara, CA). We converted seven nucleotides within
each Klf9 consensus sequence (described below) to thymi-
dines. The Klf13 5″ flanking region contains six predicted
Sp/Klf motifs. We first generated two vectors with muta-
tions in individual Sp/Klf motifs #1 or 2 (Additional file 13:
Table S5), to create pGL4.23 [Klf13] promoter1mut and
pGL4.23 [Klf13] promoter2mut), and one double mutant
(Box #1 + 2; pGL4.23 [Klf13] promoter1 + 2mut). To gener-
ate a Klf13 promoter fragment with mutations in all six
predicted Sp/Klf motifs we synthesized the entire 439 bp
fragment corresponding to that in the pGL4.23 [Klf13] pro-
moter with mutations in all six Sp/Klf motifs (Invitrogen)
and subcloned this into pGL4.23 to create pGL4.23 [Klf13]
promoter6mut. All oligonucleotides used for subcloning
and site-directed mutagenesis are given in Additional file
18: Table S9.
Generation and characterization of stable HT22 cell lines
with doxycycline (dox)-inducible Klf9
We cultured HT22 cells (gift of Dr. David Schubert) in
high-glucose DMEM (Invitrogen) supplemented with 10%
fetal bovine serum (Hyclone Laboratories, Inc., Logan,
UT), penicillin G (100 U/ml) and streptomycin sulfate
(100 μg/ml) under a humidified atmosphere of 5% CO2 at
37 °C. This cell line was originally derived from mouse
hippocampus using the Simian Virus 40 T antigen [19].
To generate stably transfected HT22 [TR/TO-Klf9] cell
lines we seeded 5 × 106 cells in 100 mm plates and trans-
fected them with 5 μg each of pCDNA4:TO-Klf9 and
pCDNA6:TR (Invitrogen) using Fugene6 (Invitrogen).
Twenty four hr after transfection we changed to selective
medium containing 100 μg/ml zeocin plus 5 μg/ml blasti-
cidin (Research Products International, Mt. Prospect, IL).
Louis, MO) and passaging with 0.25% trypsin (Gibco;
Thermo-Fisher). We then seeded trypsinized cells in 6-
well plates and expanded the clonal lines. We tested seven
clonal HT22 [TR/TO-Klf9] lines for dox-inducible Klf9
mRNA by culturing them in 6-well plates and treating
with vehicle (0.1% DMSO) or 1 μg/ml dox (Sigma; all dox
treatments were done at this concentration) for 8 h, after
which cells were harvested for RNA isolation and analysis
for Klf9 mRNA levels by RTqPCR (described below). To
test if the stable cell lines expressed functional Klf9 we
seeded cells at 5 × 104 per well in 24 well plates and co-
transfected them with pGL4.23-3xBTE (200 μg) plus
pRenilla (10 μg) (Promega Corporation, Madison, WI).
We treated transfected cells with vehicle or dox for 8 h
and harvested for dual luciferase assay (Promega). As a
control, we co-transfected parent HT22 cells with
pGL4.23-3xBTE plus a Klf9 expression vector (pCS2-Klf9)
to independently investigate the action of Klf9 on this
reporter.
For gene expression analysis we plated HT22 cells in
either 6- or 12-well plates at densities of either 2.5 × 105
or 1.25 × 105, respectively, and began treatment with dox
24 h after plating. We then harvested cells and extracted
RNA at different times after dox treatment for analysis
by RTqPCR.
For luciferase assays, we cultured cells in 24-well
plates at a density of 5 × 104 cells/well. Twenty-four
hr after plating we transfected with 200 ng/well of
the luciferase vector and 10 ng/well pRenilla plasmid
to monitor transfection efficiency, and 24 h later we
treated cells with vehicle or dox for 8 h (pGL4.23-
3xBTE vector) or 24 h (all other luciferase vectors).
We harvested cells for luciferase assay using the
Dual Luciferase Reporter Assay System (Promega)
according to the manufacturer’s instructions. Firefly
luciferase activity was quantified using a luminometer
(Femtometer FB 12; Zylux Corp) and normalized to
Renilla luciferase activity. All transfection reporter assays
were repeated at least two times with 5–6 replicates/
treatment.
RNA extraction, reverse transcription and quantitative PCR
We extracted total RNA from HT22 cells or mouse
brain (hippocampal region; see [18] for method) using
the TRIzol reagent (Invitrogen) following the manufac-
turer’s instructions. We treated total RNA with DNase 1
(20U; Roche, Basel, Switzerland) to remove contaminat-
ing genomic DNA and conducted reverse transcription
with 1 μg RNA using the High Capacity Reverse
Transcription kit with ribonuclease inhibitor (Applied
Biosystems, Life Technologies Corp, Foster City, CA).
For RTqPCR we used Taqman assays for Gapdh and
Klf9 [7] and SYBR green assays for all other genes. All
oligonucleotide primer sequences are given in Additional
file 18: Table S9. We conducted RTqPCR using an ABI
7500 fast real-time PCR machine with Absolute qPCR low
ROX mix (for Taqman assays) or Absolute qPCR SYBR
low ROX mix (ABgene, Epsom, UK). We designed
SYBR green assays using Integrated DNA Technology’s
RealTime qPCR Assay tool; where possible we designed
assays to span exon-exon boundaries. We used a relative
quantitation method using serial dilutions of a cDNA pool
to generate standard curves. We normalized all genes to
the reference gene Gapdh whose mRNA was unaffected
by treatments (data not shown.)
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Generation of stable HT22 cell lines that express
biotinylated Klf9
We produced stably transfected HT22 cell lines that ex-
press biotinylated Klf9 by culturing cells in 100 mm plates
and transfecting them with 5 μg each of pEF1α-BirA and
pEF1α-FLBIO-Klf9 (HT22 [BirA/FLBIO-Klf9]). Twenty
four hr after transfection we treated cells with 100 ug/ml
zeocin plus 1 μg/ml puromycin. To make stably trans-
fected HT22 cell lines that express only BirA (HT22
[BirA]) we transfected cells with 5 μg pEF1α-BirA. Twenty
four hr after transfection we treated cells with 100 ug/ml
zeocin. Following antibiotic selection for 5 days we iso-
lated individual cells by trypsinization using cloning cylin-
ders and subcultured them as described above.
To determine if the stably transfected cell lines
expressed the FLBIO-Klf9 fusion protein and/or BirA-V5
we analyzed nuclear extracts by Western blotting. For nu-
clear extraction we cultured HT22 [BirA] or HT22 [BirA/
FLBIO-Klf9] cells in 100-mm plates until they reached
95% confluency, collected cells with a cell scraper into
hypotonic buffer (10 mM HEPES pH 7.9, 10 mM KCl,
1 mM DTT), allowed them to swell for 30 min, then lysed
them with a motorized homogenizer and added 0.1 vol-
ume of sucrose restore buffer (50 mM HEPES pH7.9,
10 mM KCl, 1 mM DTT, 6.75% sucrose). We isolated nu-
clei by centrifugation at 4000 × g for 15 min, removed the
supernatant (the cytoplasmic fraction), resuspended nuclei
in nuclear extraction buffer (50 mM HEPES pH 7.9, .5 M
KCl, 1 mM DTT) and incubated on ice for 40 min with
vortexing every 10 min, then centrifuged for 1 h at
100,000 × g. We quantified the protein concentration of
the extracts using the Pierce assay (Thermo Scientific).
We then fractionated 40 μg of nuclear protein per lane
of a 10% SDS-PAGE gel, transferred proteins to nitro-
cellulose membrane and blocked the membrane with
SuperBlock (Thermo; following the manufacturer’s in-
structions; for BirA-V5), or with PBS containing 5%
bovine serum albumin, 10% normal goat serum, 0.5%
Triton-X (for FLBIO-Klf9). To detect BirA-V5 we incu-
bated the membrane with V5 antibody (Millipore; 1:5000
dilution) overnight before washing and incubation with
HRP-conjugated goat anti-rabbit secondary antibody for
1 h (Jackson ImmunoResearch Laboratories, Inc.); diluted
1:30,000). To detect FLBIO-Klf9 we incubated the mem-
brane with Streptavidin-HRP (Thermo; diluted 1:1000)
for 1 h. Immune or streptavidin-HRP complexes were
revealed by chemiluminescence detection using Pierce
ECL Substrate (ThermoFisher Scientific).
RNA Sequencing
For RNA-seq analysis we treated the HT22 parent line
or the HT22 [TR/TO-Klf9] line 2–1 with vehicle or dox
for 8 h. We extracted total RNA using TRIzol reagent,
then purified it using the QIAgen RNEasy kit. Library
construction and next generation sequencing was done
at the University of Michigan DNA Sequencing Core on
twelve RNA samples (1 μg/sample) representing the four
treatments (n = 3/treatment). The twelve samples were
analyzed in two lanes using an Illumina 2000 HI-seq ma-
chine, which generated between 23,555,652 and
50,630,253 million reads per sample. The sequencing
reads were de-multiplexed by the University of Michigan
DNA Sequencing Core, evaluated and filtered using
FastQC software (http://www.bioinformatics.babraha-
m.ac.uk/projects/fastqc/) and aligned to the mouse gen-
ome (build mm8) using the program Bowtie [21]. We
quantified mRNA levels using DESeq [22]. To calculate
gene expression ratios, counts from all genes that were
detected by RNA-seq in each cell line were average by
treatment, and average counts from dox-treated cells
were divided by average counts from vehicle-treated
cells. Genes where no reads were mapped in one or both
treatments were excluded from the analysis.
Chromatin extraction and precipitation
Chromatin extraction and chromatin immunoprecipita-
tion (ChIP) were done as described previously [5, 7, 18].
We grew HT22 cells in 100 mm plates, and for some
experiments (e.g., preparation of samples for ChSP-seq
libraries) we pooled cells from two plates to increase the
amount of chromatin recovered. After washing with
Dulbecco’s Phosphate Buffered Saline (DPBS), we treated
cells with 1% formaldehyde for 10 min followed by treat-
ment for 10 min with the bifunctional crosslinking agent
dithiobis (succinimidyl propionate) (DSP; 200 nM;
Thermo Scientific) before extracting chromatin. We
sonicated the chromatin using an M220 Focused-
Ultrasonicator (Covaris, Woburn, MA) for 20 min
using a 2% duty factor, and checked that the DNA had
been sheared to 500–600 bp by electrophoresis on a 1%
Tris acetate EDTA agarose gel. We then flash-froze the
chromatin with liquid nitrogen and stored it at − 80 °C
until analysis. For each ChIP reaction we used 5 μg puri-
fied IgG of goat anti-mBTEB-C17, goat anti-mSin3a-K20,
or normal goat IgG (Santa Cruz Biosciences, Santa
Cruz, CA).
We conducted ChSP following the method of Rama-
doss and colleagues [79]. We first washed MyOne T1
streptavidin-conjugated Dynabeads (Invitrogen; 50 ul/
reaction) three times with phosphate buffered saline
(PBS; pH 7.4), then mixed the beads with 50 μg of
chromatin (5 μg of chromatin was reserved for input)
and the total volume was brought to 1 ml with ChIP di-
lution buffer (.01% SDS, 1.1% Triton X-100, 1.2 mM
EDTA, 16.7 mM Tris–HCl pH 8.1, 150 mM NaCl). The
chromatin and beads were rocked overnight at 4 °C.
The beads were then collected by magnet and the
supernatant removed, then washed three times with
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1 ml of 0.5× RIPA buffer (5 mM Tris-Cl pH 8.0,
0.5 mM EDTA, 0.25 mM EGTA, 70 mM NaCl, 0.5%
Triton X-100, 0.05% sodium deoxycholate, 0.05% SDS).
After the final wash, we resuspended the beads in
decrosslinking buffer (50 mM Tris-Cl pH 8.0, 1 mM
EDTA, 100 mM NaCl, 0.5% SDS) and removed crosslinks
by incubation at 65 °C overnight (after this step the input
samples were processed simultaneously with the ChSP
samples). The DNA was then extracted with phenol:cho-
loroform:isoamyl alcohol (Invitrogen) and precipitated
with 0.3 M sodium acetate and 100% ethanol. We added
20 μg (1 μl) molecular biology-grade glycogen (Roche)
before precipitation to visualize DNA pellets. After pre-
cipitation we resuspended the DNA in 25 μl nuclease-free
water and analyzed by qPCR for the Klf13 promoter and
intronic regions. Samples were quantified as a percentage
of corresponding input sample.
Chromatin streptavidin precipitation sequencing
For ChSP sequencing (ChSP-seq) we prepared DNA
precipitated from 150 μg of chromatin per sample as
described above, and submitted ten samples to the Uni-
versity of Michigan DNA Sequencing Core for next
generation sequencing: one input DNA sample (pooled
from four input samples) from each of the two cell lines
HT22 [BirA] and HT22 [BirA/FLBIO-Klf9], and four
ChSP DNA samples from each cell line. We ran 5 sam-
ples per lane which generated between 18,818,940 and
27,816,127 million reads per sample. We filtered the se-
quenced reads using FastQC and aligned them to the
mouse mm8 genome using Bowtie [21]. We then used
the NCBI Genome Remapping Service to transfer
peaks to the mm10 build. We identified peaks using
MACS [25] and PePr software [24] and assigned
peaks to genes using ChIP-enrich [28]. Additional
analysis of the locations of peaks and mapping of
regions of highest peak density was conducted using
Cis-regulatory Element Annotation System software
[29]. We clustered peaks by shape using the program
SIC-ChIP [31]. Motif enrichment was analyzed using
HOMER [30], and gene ontology analysis was done
using GeneCoDis [35–37].
Generation of HT22 Klf9-knockdown and knockout cells
using CRISPR/Cas9 genome editing
We constructed a guide RNA (gRNA)/Cas9 expression
plasmid (OriGene) containing the gRNA sequence 5′
ggggcgctccggaagccgag 3′ (this gRNA targets a sequence
in the 5′ region of the Klf9 gene). We transfected the
parent HT22 cell line with this vector, which expresses en-
hanced green fluorescent protein (EGFP), and conducted
fluorescence-assisted-cell sorting (FACS) at the University
of Michigan Flow Cytometry core to isolate EGFP positive
cells. We isolated clonal lines of the FACS-sorted cells as
described above, extracted genomic DNA and screened
for mutations by direct DNA sequencing of PCR-
amplified DNA corresponding to Klf9 exon 1 subcloned
into the pGEM T-easy vector (Promega). We selected two
Klf9-null lines (defined by the absence of a wild-type Klf9
allele and the presence of mutations predicted to create
nonsense or prematurely truncated proteins), cultured
them simultaneously with the parent HT22 line in 6-well
tissue culture plates, harvested cells, extracted RNA and
analyzed gene expression by RTqPCR.
Analysis of cell cycle by flow cytometry
Approximately 150,000 cells from the HT22 parent,
CRISPR Line 1 and CRISPR Line 2 cell lines were
plated in 10 cm plates in DMEM supplemented with
10% FBS. Sixteen hr after plating we changed the
medium to DMEM containing 2% serum. After a further
72 h we trypsinized cells and pelleted them by centrifuga-
tion for 5 min at 200 × g. The cells were then washed by
resuspending the pellet in DPBS containing 1% BSA and
pelleting by centrifugation at 1000 rpm for 5 min. Cells
were then fixed for 15 min at room temperature by re-
suspending the pellet in 100 ul of 4% paraformaldehyde
in DPBS. The fixed cells were then centrifuged at
1000 rpm for 5 min, then washed in DPBS containing
1% BSA and centrifuged again. Cells were perme-
abilized by resuspension in 100 μL of 1× Saponin buffer
(Click-iT EdU Flow Cytometry Assay Kit, Invitrogen)
containing 1% BSA. Cells were stained in darkness for
30 min at room temperature using FxCycle Violet
(Thermo Fisher) diluted 1:1000 in DPBS, and analyzed
using an Attune Cytometer (Applied Biosystems) at
405 nm wavelength. The relative proportion of cells in
G1/G0 and M phases was determined using ModFit LT
(Verity Software House, Topsham, ME).
Animals
We purchased C57/BL6 mice from Jackson Laboratories
(Sacramento, CA) and maintained them on a 12 L:12D
photoperiod with food and water provided ad libitum.
Animals were killed by rapid decapitation and a sec-
tion of the brain that included the hippocampus was
dissected and flash-frozen for subsequent chromatin
or RNA extraction (see above). Mice null for Klf9
were bred from animals provided by Dr. Yoshiaki
Fuji-Kuriyama and Dr. Frank Simmen [6]. All procedures
involving animals were approved by the Institutional
Animal Care and Use Committee of the University of
Michigan.
Statistical analysis
Derived (normalized) values from RTqPCR, ChIP, ChSP
and dual luciferase assays were log10 transformed before
analysis by one-way ANOVA followed by the Holm-Sidak
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multiple comparison test, or by unpaired Student’s t-test
using SYSTAT (version 13; SPSS Inc., Chicago, IL). Data
are reported as the mean ± standard error of the mean
(SEM). When non-parametric tests were required, the
Kruskal-Wallace one-way analysis of variance or Mann–
Whitney U-Test were used. Results of the statistical ana-
lyses are reported in the figure legends.
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